Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12967-020-02476-9 http://scihub22266oqcxt.onion/10.1186/s12967-020-02476-9 33059719!7558548!33059719     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Transl+Med 2020 ; 18 (1): 390 Nephropedia Template TP {{tp|p=33059719|t=2020. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals |pdf=|usr=}}{{33059719}} gab.com Text A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals JO: J Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=33059719 #FOAvip While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing, there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would be a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development and therefore rapid deployment at the onset of an outbreak. Targeting host-pathways and cellular proteins that are hijacked by viruses can potentially offer broad-spectrum targets for the development of future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to the development and selection of drug resistant mutations. Given that most approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations. Twit Text FOAVip A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals ????J Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=33059719 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33059719 #FOAvip English Wikipedia <ref>{{Cite pmid|33059719}}</ref> A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals #MMPMID33059719 Chitalia VC; Munawar AH J Transl Med 2020[Oct]; 18 (1): 390 PMID33059719show ga While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing, there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would be a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development and therefore rapid deployment at the onset of an outbreak. Targeting host-pathways and cellular proteins that are hijacked by viruses can potentially offer broad-spectrum targets for the development of future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to the development and selection of drug resistant mutations. Given that most approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations. |*Antiviral Agents/classification/pharmacology/therapeutic use[MESH] |*Drug Discovery/organization & administration/standards/trends[MESH] |*Health Services Needs and Demand/organization & administration/standards/trends[MESH] |Anti-Inflammatory Agents/pharmacology/therapeutic use[MESH] |Betacoronavirus/*drug effects/genetics[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology/virology[MESH] |Drug Delivery Systems/methods/standards[MESH] |Global Health[MESH] |Host-Pathogen Interactions/*drug effects[MESH] |Humans[MESH] |Mutagenesis/drug effects[MESH] |Needs Assessment/organization & administration/standards[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/virology[MESH] |SARS-CoV-2[MESH]A painful lesson from the COVID-19 pandemic: the need for broad-spectr(epmc).pdf DeepDyve Pubget Overpricing